Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.
Alexa Tomassi
Advertisement
Communications officer at Yale School of Medicine
Articles by Alexa Tomassi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN
2
Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials
3
Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD
4
COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch
5